Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

CD8 T Cell Immune Signatures in Autoimmune Myasthenia Gravis
Autoimmune Neurology
N6 - Neuroscience in the Clinic: Myasthenia Gravis: From Pathogenesis to Targeted Therapies (4:00 PM-4:15 PM)
001

Myasthenia gravis (MG) is a chronic autoimmune disease mediated by T cells. While previous studies have predominately focused on CD4 T cells in MG pathogen, our research seeks to examine the uncertain role of CD8 T cells.

To explore the role of CD8 T cells in myathenia gravis. 

Multi-color flow cytometry was performed on CD8 T cells among MG patients (N=42) with no immunosuppressant (No-IS), those treated with steroids and healthy controls (HC) (N=20). IsoPlexis single-cell platform was applied to a subset of patients to detect cytokine production prior to and post steroid treatment (N=12). NanoString RNA sequencing of 752 autoimmune related genes was performed on CD8 T cells to validate the cytokine changes (N=26).

Memory (CD27+) and Exhausted (CTLA4+, PD-1+, EMOES+) CD8 T cell were increased in No-IS MG patients. In unbiased Self-Organizing Maps (FlowSOM), central memory and CXCR5+ CD8 T cells were increased in No-IS compared to HC and decreased post treatment. Single-cell analysis detected elevated frequencies of effector and inflammatory cytokines, including granzyme B, IFN-g, IL-9, MIP-1b, TNF-a, IL-17A, GM-CSF, IL-12, and MIP-1a in the No-IS group. Effector and inflammatory cytokines and frequencies of polyfunctional CD8 T cells significantly decreased with steroids treatment. RNA sequencing assays are in process and results will be presented at the conference.

Analysis of CD8 T cells demonstrates an effector phenotype with prominent polyfunctional inflammatory cytokine function in MG patients. Steroid treatment reduces the CD8 T cell proinflammatory phenotype. This data suggests CD8 T cells contribute to MG pathogenesis and may potentially serve as a biomarker for monitoring response to treatment.

Authors/Disclosures
Yingkai Li, MD, PhD (Duke University)
PRESENTER
Dr. Li has nothing to disclose.
Vern C. Juel, MD, FAAN (Duke University Medical Center) Dr. Juel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunovant. Dr. Juel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Juel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Accordant Health Services. Dr. Juel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. The institution of Dr. Juel has received research support from argenx. The institution of Dr. Juel has received research support from Alexion. The institution of Dr. Juel has received research support from Janssen. The institution of Dr. Juel has received research support from NIH Rare Diseases Network.
Tabitha Karatz (Duke University) No disclosure on file
No disclosure on file
Jeff Guptill, MD, FAAN (argenx US) Dr. Guptill has received personal compensation for serving as an employee of argenx. Dr. Guptill has stock in argenx.
Simon Gregory (Duke University) No disclosure on file